Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patient preference for home versus hospital subcutaneous pertuzumab + trastuzumab administration in HER2-positive early/locally advanced breast cancer
2021-002346-33Phase 3Active
- Sponsor
- Roche
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pertuzumab and trastuzumab in breast cancer (2 arms), sponsored by Roche. Primary endpoint: Patient preference for home versus hospital subcutaneous administration. Started Mar 2022; status: active.
02
Drugs
pertuzumabtrastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2021-002346-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002346-33.